Recently, the Advanced Prostate Cancer Consensus Conference (APCCC) was held in Lugano, Switzerland. Professor Wei Qiang, Specialty Director of the Urology Department and Director of the Urology Research Institute at West China Hospital, Sichuan University (WCH), led his team to the conference. He was also invited, as the representative from mainland China, to participate in the APCCC expert consensus panel.

Professor Wei, who serves as the Chair of the Prostate Cancer Expert Committee of the Chinese Society of Clinical Oncology (CSCO), delivered an oral presentation on the epidemiological characteristics of prostate cancer in China. He also presented the recent progress and achievements made by the Primary Care Subgroup of the Chinese Urological Association, which he leads. These advancements include primary care strategies for prostate cancer, training for primary care physicians, promotion of standardized diagnosis and treatment, and the development of relevant clinical guidelines. His presentation demonstrated the practical outcomes of China's efforts in building a prostate cancer diagnosis and treatment system and strengthening primary care interventions.

During the conference, Professor Wei's team presented four original research studies. The topics included environmental exposure characteristics in relation to prostate cancer progression, circadian rhythms and prostate cancer lineage plasticity, proteogenomic features of prostate cancer development, and the interaction between blood tumor-related gene variants and prostate cancer. These presentations highlighted the Department of Urology's ongoing and significant contributions to basic research and clinical translation in prostate cancer.

Conference Chair Professor Silke Gillessen, Director of the Oncology Institute of Southern Switzerland (IOSI), also met with Professor Wei's team. The two sides exchanged views on precision diagnosis and treatment of prostate cancer, building translational research platforms, international multi-center collaboration, and the development of young researchers. The discussion laid a strong foundation for deepening future international academic cooperation.

APCCC is one of the world's most influential international consensus conferences in the field of advanced prostate cancer diagnosis and treatment. Its expert consensus panel includes more than 100 renowned specialists in the field. The consensus results will be published after the conference in leading oncology and urology journals, serving as a key reference for personalized treatment and clinical decision-making for advanced prostate cancer worldwide.